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Introduction
Prostate cancer (PCa) is a leading cause of male cancer
mortality in the USA.1 Diagnosis of PCa can be made
by transrectal ultrasound (TRUS)-guided biopsy of
the prostate or transurethral resection of the prostate
(TURP). Prostate-specific antigen (PSA) has been
proved to be a very useful tumor marker for the
prostate, but it is not specific for PCa.2 An abnormal
digital rectal examination (DRE) and/or elevated serum
PSA can indicate PCa. The technique of TRUS-guided
biopsy of the prostate has changed from the sextant
biopsy in 1980 to saturation biopsy nowadays. It is sug-
gested that the more biopsy cores that are taken, the
more cancer one finds.3 Most PCa is located in the
peripheral zone, which is easily confirmed by TRUS-
guided biopsy, but it is hard to diagnose PCa in the tran-
sitional zone.3,4 Therefore, biopsies in the transitional
zone of the prostate have been suggested for patients
with elevated PSA and negative results from extended
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multisite biopsies.5–7 Puppo et al have suggested that
diagnostic TURP has a high diagnostic power for
PCa,8 but risk of morbidity with TURP should not be
ignored.3 However, other authors have reported a lower
diagnostic yield (range, 20–30%) for TURP.3 Kitamura
et al concluded that many cancers diagnosed by TURP
might be clinically insignificant.9
van Renterghem et al reported that their patients
with mild lower urinary tract symptoms (LUTS), ele-
vated PSA and negative multisite biopsies underwent
TURP, and 9.8% of them had PCa.10 Patients with mod-
erate LUTS [International Prostate Symptom Score
(IPSS), 8–19] and elevated PSA (≥4ng/mL) or abnor-
mal findings by DRE are recommended to receive
TRUS-guided biopsy of the prostate or TURP, but
which procedure is better for diagnosis of PCa needs
further evaluation. To compare TRUS-guided biopsy
of the prostate and TURP for diagnosis of PCa in
patients with moderate LUTSs, we conducted a ret-
rospective study.
Methods
PSA, DRE, TRUS and IPSS were routinely checked for
evaluation of all the patients (age ≥50 years) with LUTS,
and TRUS was performed by using real-time scanning
with a rotating 7.5-MHz transducer (Bruel & Kjacer,
Copenhagen, Denmark) at our hospital. Between
January 2004 and December 2008, 601 patients with
moderate LUTS (IPSS, 8–19) and PSA ≥ 4 ng/mL, or
abnormal findings by DRE (such as palpable nodule
or hard consistency), were included for evaluation. All
the patients were initially treated with α-blocker, and
no patients received 5α reductase inhibitor. Eighty-
one patients with a history of acute urinary retention,
acute prostatitis, urethritis, or refusal to undergo fur-
ther examinations were excluded. The remaining 520
patients, aged 50.3–81.5 years, satisfied the inclusion
criteria and were enrolled for evaluation. These 520
subjects were recommended to receive TRUS-guided
biopsy of the prostate (TRUS biopsy group) or TURP
(TURP group) because of the possibility of PCa,
according to the patients’ choice after full explanation
by the doctors. Patients in the TURP group did not
have previous biopsy, and they chose TURP because
there was no specific improvement or side effects after
α-blocker treatment. PSA was checked every 3–6
months for patients without PCa in the TURP group,
and patients were recommended to receive biopsy if
an increase in PSA was noticed. Prostate volume was
measured by TRUS, with the formula being 0.52 ×
length × width × height.
Biopsy of the prostate was done with a spring-
loaded automatic biopsy gun under TRUS guidance
and local anesthesia (application of xylocaine jelly over
the rectum). We used 12-core biopsy including 6 lat-
erals, 2 from the transitional zone and 4 from the lat-
eral peripheral zone, in addition to the conventional
sextant biopsies, as described by Durkan et al to detect
PCa.5 Repeated biopsy was recommended if high-
grade prostatic intraepithelial neoplasia or increased
PSA (higher than previous level) was noted 6 months
after the first negative biopsy. A continuous-flow resec-
toscope was used to perform TURP until the surgical
capsule was found (nearing perforation), without supra-
pubic cystostomy drainage. All surgical specimens were
weighed and sent for pathological examinations. Bone
scanning (whole-body bone scintigraphy) and computed
tomography or magnetic resonance imaging were per-
formed in all the patients for clinical staging when PCa
was confirmed. Tumor grading was classified as low
(2–4), intermediate (5–7) or high (8–10) according to the
Gleason score. Clinically insignificant PCa (T1N0M0)
was defined as low-grade tumor, PSA < 10 ng/mL,
< 5% of PCa in the resected tissue by TURP, and no
evidence of metastasis. The study was approved by
the institutional review board of Taipei City Hospital.
The χ2 test and Mann–Whitney U test were used
for statistical analysis, with p < 0.05 considered to be
statistically significant.
Results
Of the 520 patients, 379 (72.9%) were in the TRUS
biopsy group and 141 (27.1%) in the TURP group.
PCa was detected in 80 (21.1%) patients in the TRUS
biopsy group and in 27 (19.1%) in the TURP group.
The baseline characteristics of all 520 patients and
107 with PCa are illustrated in Table 1. No significant
differences in age, PSA, IPSS and prostate volume
were noted between the 2 groups (Table 1). Patients
in the TURP group had lower maximal urine flow
rate than those in the TRUS biopsy group (12.5 ± 3.7
vs. 12.9 ± 4.1 mL/sec; Table 1), but the difference
was not significant (p = 0.63). The mean number of
TRUS-guided biopsies that were undertaken in 80
patients with PCa was 1.4 (1 in 52 patients, 2 in 22, 
3 in 5, and 4 in 1). Of 299 subjects without PCa in the
TRUS biopsy group, 30 had undergone prior biopsy
at another hospital, and the number of biopsies was 
1 in 199, 2 in 80, and 3 in 20 patients. The mean
weight of TURP specimen was 28.9g (range, 13–53g).
The PCa detection rates were 0%, 12.1%, 17.9%,
21.6% and 53.4% in the TRUS biopsy group and 6.8%,
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19.4%, 20%, 22.2% and 58.8% in the TURP group when
PSA was < 4 ng/mL, 4–10 ng/mL, 10–20 ng/mL,
20–30ng/mL, and >30ng/mL, respectively (Table 1).
Significantly higher PCa detection rate was noted in
patients in the TURP group than the TRUS biopsy
group when PSA was < 4 ng/mL (Table 1). IPSS sig-
nificantly decreased from 14.0 ± 4.2 to 5.5 ± 2.5 after
TURP. Major complication rate for TURP (including
TURP syndrome and blood transfusion due to severe
hematuria) was 3.5% (5/141), and for TRUS-guided
biopsy (including urinary sepsis and blood transfusion
due to severe hematuria) was 1.3% (5/379).
There was bone metastasis in 22 patients (27.5%) in
the TRUS biopsy group and 7 (25.9%) in the TURP
group; the difference was not significant. Of the 22
patients in the TRUS group with bone metastasis,
PSA was > 30 ng/mL in 19, 20–30 ng/mL in 2, and
10–20 ng/mL in 1. Of the 7 patients in the TURP
group with bone metastasis, PSA was > 30 ng/mL in
6, and 20–30 ng/mL in 1. Clinically localized PCa
(T1–2N0M0 proved by computed tomography or
magnetic resonance imaging) was found in 46 (57.5%)
patients in the TRUS biopsy group and 16 (59.3%) 
in the TURP group, with no significant difference
between the 2 groups. The proportion of cancer in
the resected prostate tissue was < 5% in 10 patients,
5–10% in 8 and > 10% in 9, and 37% (10/27) was
clinically insignificant tumor by TURP. The percent-
age of low-, intermediate- and high-grade tumor was
5% (4/80), 51.3% (41/80), and 43.7 (35/80) in
patients in the TRUS group, and 11.1% (3/27),
51.9% (14/27), and 37% (10/27) in patients in the
TURP group, respectively. The percentage of low-
grade tumor was significantly higher in patients in the
TURP group than the TRUS group (11.1% vs. 5%).
Of 299 patients without PCa in the TRUS biopsy
group, 35 received TURP and 2 had PCa. Of 114
subjects without PCa in the TURP group, 20 under-
went TRUS biopsy due to increasing PSA and 2 had
PCa. In these 4 patients with PCa, PSA was
35 ng/mL, 45 ng/mL, 52 ng/mL, and 38 ng/mL,
respectively.
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Table 1. Baseline characteristics of all the patients and those with prostate cancer*†
Group 1 Group 2 
p
PCa in Group 1 PCa in Group 2 
p
(n = 379) (n = 141) (n = 80) (n = 27)
Age (yr) 64.5 ± 11.5 [186] 66.2 ± 12.6 [72] 0.61 63.7 ± 12.9 [38] 66.4 ± 14.2 [12] 0.73
PSA (ng/mL) 21.1 ± 16.4 [241] 14.1 ± 13.7 [103] 0.08 22.2 ± 17.0 [37] 15.5 ± 15.1 [13] 0.07
< 4 2.9 ± 1.0 [6] (n = 12) 2.8 ± 0.9 [30] (n = 58) 0.86 2.9 ± 1.0 [2] 0.02
PCa detection 0% (n = 0) 6.8% (n = 4)
rate
4–10 7.1 ± 1.9 [90] (n = 165) 6.9 ± 1.8 [21] (n = 36) 0.75 7.8 ± 2.1 [12] 7.1 ± 2.0 [5] 0.45
PCa detection 12.1% (n = 20) 19.4% (n = 7) 0.72
rate
10–20 15.3 ± 3.8 [28] (n = 56) 15.0 ± 3.2 [10] (n = 20) 0.73 16.1 ± 3.9 [6] 15.5 ± 3.3 [2] 0.67
PCa detection 17.9% (n = 10) 20.0% (n = 4) 0.95
rate
20–30 25.4 ± 3.6 [46] (n = 88) 24.9 ± 3.8 [4] (n = 9) 0.69 26.2 ± 4.1 [11] 25.7 ± 4.3 [1] 0.62
PCa detection 21.6% (n = 19) 22.2% (n = 2) 0.65
rate
> 30 62.5 ± 22.5 [32] (n = 58) 57.4 ± 23.8 [11] (n = 18) 0.25 66.3 ± 26.5 [18] 63.9 ± 25.6 [6] 0.26
PCa detection 53.4% (n = 31) 58.8% (n = 10) 0.51
rate
IPSS 13.1 ± 3.9 [190] 14.0 ± 4.2 [70] 0.51 12.9 ± 3.9 [39] 13.8 ± 4.3 [13] 0.54
Maximal flow rate 12.9 ± 4.1 [191] 12.5 ± 3.7 [71] 0.63 12.7 ± 4.0 [41] 12.3 ± 3.8 [14] 0.61
Clinically localized 57.5% (n = 46) 59.3% (n = 16)
PCa
Bone metastasis 27.5% (n = 22) 25.9% (n = 7)
Prostate volume 40.4 ± 12.5 [188] 38.5 ± 11.8 [72] 0.56 38.9 ± 12.2 [42] 37.4 ± 11.5 [13] 0.63
(cm3)
*Data are presented as mean ± standard deviation [mean rank]; †Mann–Whitney U and c2 tests were used for statistical analysis, with p < 0.05 considered signifi-
cant. Group 1 = TRUS biopsy group; Group 2 = TURP group; PCa = prostate cancer; PSA = prostate-specific antigen; IPSS = International Prostate Symptom Score.
Discussion
Patients with elevated PSA or abnormal DRE findings
are recommended to receive TRUS-guided biopsy of
the prostate initially, and repeat biopsy is recommended
unless PSA is normalized. In addition, Chappell and
McLoughlin3 reported that repeat biopsy is suggested
for patients with high-grade prostatic intraepithelial
neoplasia,11 low ratio of free to total PSA, high PSA
density, or family history of PCa. However, extended
multisite biopsies are not harmless and might cause
discomfort to the patient.12 Most PCa in the transi-
tion zone is located anteriorly and is not detected if the
biopsy needle is only directed at the center of the
tumor.13,14 PCa in the transition zone is more often
of low grade and has less chance of capsular penetra-
tion and metastasis than peripheral zone cancers.15 In
the present study, in patients with PSA < 4 ng/mL, no
cancer (0/12) was found by needle biopsy, but 4 cancers
(4/58) were found by TURP. Additionally, all 4 can-
cers were clinically insignificant (<5% in resected tissue)
and low grade (Gleason score, 2–4) tumors. Further-
more, the specimens from TURP were not obtained
with a whole-mount procedure, so the detection rate
of PCa might have been underestimated.
van Renterghem et al reported that patients with
mild LUTS and elevated PSA might have bladder outlet
obstruction and benefit from TURP.10 Lin et al sug-
gested that the chance of detecting PCa beyond a third
biopsy is low, and TURP might be an alternative pro-
cedure, especially in patients with elevated PSA and
obstructive symptoms.16 However, how many biopsies
are adequate remains debatable. Startsev et al stated that
TURP could detect cancer in the transitional zone in
patients with LUTS and negative prostate biopsy.17
Reich et al suggested that TURP is very effective and
durable in alleviating LUTS due to benign prostate
hyperplasia.18 Patients with severe LUTS might be
prone to select TURP, and patients with mild LUTS
could be more likely to choose prostate biopsy if cancer
is suspected. In addition, TRUS biopsy might be sug-
gested first for younger patients (< 70 years) and PSA
> 10 ng/mL. In the present study, we included patients
with moderate LUTS (IPSS, 8–19) for evaluation.
Patients with moderate LUTS had significant improve-
ment after TURP, and about 20% had PCa, but all
these patients had elevated PSA or abnormal DRE
findings. Therefore, patients with moderate LUTS
and elevated PSA might have a higher incidence of
PCa than those without LUTS, but the etiology needs
further evaluation. Furthermore, TURP was not supe-
rior to TRUS-guided biopsy for diagnosis of PCa in
patients with moderate LUTS and PSA ≥ 4 ng/mL.
In the study by Puppo et al,8 7 patients (20%) had
PCa diagnosed by TURP and biopsy of the peripheral
zone of the prostate after repeated negative needle
biopsy and elevated PSA. Also, the proportion of cancer
in the resected prostate tissue was 2–4% in 5 cases, 6% in
1, and 8% in another. In the present study, we found that
about 37% (10/27) of patients had clinically insignifi-
cant tumor (< 5% of PCa in the resected tissue) by
TURP without previous needle biopsy. In addition, of
the 10 patients, 4 had PSA <4ng/mL and 6 had PSA
between 4 and 10ng/mL. Furthermore, the percentage
of low-grade tumor was higher in the patients who
underwent TURP than in those who received needle
biopsy. Until now, there has been controversy about the
role of diagnostic TURP.8,9,13,16,19–21 Bratt reported that
diagnostic TURP might be of value for patients with
large prostate and continuously rising PSA,22 and if no
cancer is found and PSA is increasing after TURP, the
remaining smaller prostate can be more easily sampled
by TRUS-guided biopsy. van Renterghem et al con-
cluded that TURP can be a useful diagnostic tool for
PCa in patients with mild LUTS but elevated PSA,10
and that special attention is needed over the lateral and
anterior part of the prostate during diagnostic TURP.
Shen et al23 suggested that TURP combined with addi-
tional systemic prostate biopsy can increase the detec-
tion rate of PCa, and is a relatively safe treatment. In the
present study, TURP could resect all the tumors com-
pletely, and might have increased the diagnostic yield of
PCa and detected more clinically insignificant tumor,
especially in patients with moderate LUTS and PSA
< 4 ng/mL. Additionally, the lower prevalence of PCa
and smaller prostate in Asian patients might explain
why diagnostic TURP had a higher chance of detect-
ing PCa than needle biopsy in patients with PSA
< 4 ng/mL. Therefore, TURP might have a higher
PCa detection rate than needle biopsy in patients with
moderate LUTS and PSA < 4 ng/mL. Although the
baseline characteristics between the 2 groups were
similar, they could be different in nature. Lack of ran-
dom allocation was a major limitation of the present
study. However, TRUS biopsy and TURP were simul-
taneously and equally provided for all the patients
after full explanation to avoid selection bias.
D’Ambrosio et al24 reported that a prior history of
TURP does not affect outcome in patients who sub-
sequently develop PCa. Eastham et al25 suggested that
patients with clinically localized PCa managed with-
out curative intent have about a 15% risk of local pro-
gression within 10 years. Akgul et al26 suggested that
TURP can cause cautery artifacts in resected prostate
tissue, which might influence interpretation by pa-
thologists. Therefore, more effort should be taken to
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evaluate the scientific basis for TURP as a diagnostic
tool for PCa, and whether it will affect the outcome
of further treatment.
In conclusion, TURP was not superior to TRUS-
guided biopsy of the prostate for detection of PCa in
patients with moderate LUTS and PSA ≥ 4 ng/mL.
However, TURP might have had a greater chance for
detection of clinically insignificant and low-grade PCa
than TRUS-guided biopsy of the prostate in patients
with moderate LUTS, and abnormal DRE findings and
PSA < 4 ng/mL, but the case number was small and
lacked random allocation. Therefore, we need more
subjects, longer follow-up, and a prospective study
design for further clarification.
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